Cassava Sciences
Price & Volume
Stats
See more52W Range | $2.23-$42.20 |
Market Cap | $132.3M |
Shares Short | 16M |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | -$67.8M |
Diluted EPS | -$1.38 |
News
See moreYahoo Finance • yesterday
SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Yahoo Finance • 2 days ago
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAVA
Yahoo Finance • 5 days ago
SAVA Announcement: Contact Kessler Topaz Meltzer & Check, LLP About the Securities Fraud Class Action Lawsuit Filed Against Cassava Sciences, Inc. (SAVA)
Yahoo Finance • 3 months ago
Cassava Sciences, Inc. (SAVA): Jim Cramer Says Eli Lilly Has The Edge
About
CEO | Mr. Richard Jon Barry |
Address | 6801 N. Capital of Texas Highway, Austin, TX, United States, 78731 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 29 |
